Aastrom Biosciences Inc (NASDAQ:ASTM)

Aastrom's been taken to the woodshed so many times in the last so many times in the last couple of years that I've lost track. Their latest misadventure is the discontinuation of the much-hyped REVIVE-CLI trial of their tissue repair stem cells for peripheral artery disease, apparently due to a consummate lack of interest in enrollment. That's quite a come down from the heady days of 2011 where Aastronomers roamed Seeking Alpha and the message boards shouting down anyone who expressed concern about the lack of effect of the therapy on amputation rates.

The PAD indication now seems to have vanished under the shifting sands of drug development, and the company's sole focus is the ixCELL-DCM phase IIb trial of catheter-administered ixymyelocel-T for dilated cardiomyopathy. The trial won't be fully enrolled until 2014 and topline data won't appear until at least 2015, assuming that enrollment isn't substantially slower than planned. With Aastrom an assumption like that isn't exactly safe, and considering that cash is only 14M and operations will be funded by an ongoing ATM, it is certainly possible that Aastrom stock is headed for more weakness and another reverse split. There are much better places to put your spec money. Nevertheless, for CAPS purposes I'll enter a short-term outperform looking for a a modest rebound at these levels.

Losing money. Continuing slide. Harder to sell new shares.

I don't see how injected stem cells into someone's arteries will reduce plaque. Would someone like to explain that to me?

The use of a patient's own stem cells to remake their own cardiovascular tissue is a game changer for medical sciences. This could be a game changer for the health of many people.

Financing has finally happened. Investors will swarm to this stock. They have been waiting

waiting for the phase 3 results, go ASTM

improves peoples lives with stem cells introduced into hearts making people regain their lives the heart increases its blood flow and people can walk and exercise again those peoplewho had very little chance even with heart surgery

risk

rated buy. cell structure is the future?

While I am almost 100% skeptical of Garza's pump on biomedreports.com, I do find that ASTM will have a very good chance to demonstrate historical stem cell therapy first in CLI.

The interim data (n=46) was significant. But the number of patients was small, treatment time was only 6 months.

We will see the whole data set (n=86) on Nov 18. This is a phase IIb, randomized, placebo-controlled, and double-blinded trial. Half of patients will have a treatment of 12 months. We don't have to wait too long to see the data.

If the data is significant, ASTM will triple its price. There are numerous cases in biotech that may be called "black swans".

As the recent CLI trial by Sanofi/Vical has failed, the significance of ASTM stem cell therapy will be enormous should the data be good.

Let's wait and see.

DCM patient(see on the webpages of ASTM) is alive and well. Motley Fools report does not recognize that. And that is Insane. Who is paying you to discredit ASTM. You guys must be out of your mind, just like Cramer!!
Read the report by Scimitar and Zacks...

Going to phase 3 and promising result at phase 2B. Ischemia therapy - anything that improves patient condition at this stage is an improvement over amputation.

They will need time to get the studies done. This stuff works and very exciting to see it all come alive and make a lot of money investing....

Using audlt stem cells may take the edge off the whole stem cell debate. They will need to push hard the "adult" angle to come out a winner.

Their TRC's are non-invasive, personal blood stem cells, being proven a success in clinics and create no side affects. Also non-controversal and morally acceptable.

wyn harter

Flucuates between .50 and 5.00